Please assess the completion status of the following clinical trial:

Trial Title: BT200 in Hereditary Bleeding Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:To be eligible for this study, patients must meet all of the following inclusion criteria:~1. Hereditary bleeding disorder:~   * Congenital hemophilia A without inhibitors with a prophylactic treatment regime~  * Heterozygous carriers of hemophilia A with subnormal FVIII levels~  * VWD Type 1, Vicenza type~  * VWD Type 2b~2. Male or female, age ≥18-70 years old at Screening~3. If female, must be post-menopausal or surgically sterilized~4. Able to comprehend and to give informed consent~5. Able to cooperate with the Investigator, to comply with the requirements of the study, and to complete the full sequence of protocol-related procedures -~Exclusion Criteria: Patients meeting any of the following criteria will be excluded from the study:~1. Clinically significant medical history or ongoing chronic illness that would jeopardize the safety of the patient or compromise the quality of the data derived from his/her participation in this study~2. Medical History of spontaneous (not FVIII or FEIBA-associated) venous or arterial thromboembolic events~3. History of significant drug allergy or anaphylactic reactions~4. Substance abuse, mental illness, or any reason that makes it unlikely in the judgment of the Investigator for the patient to be able to comply fully with study procedures~5. Use of medication during 2 weeks before the start of the study, which in the judgment of the Investigator may adversely affect the patient's welfare or the integrity of the study's results~6. Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days or 5 elimination half-lives (whichever is longer) prior to treatment start -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Subcutaneous (SC) injection:~BT200 dose 3 mg on Day 0, Day 4, and again on Day 7 BT200 dose titrated thereafter between 3 and 9 mg on Days 14, 21, and 28. It is anticipated that dose adjustments will be performed in 2 mg steps. The 9 mg dose will only be applied on day 28 in exceptional circumstances, if no relevant changes in pharmacodynamic and safety parameters will be observed on day 21.

Based on this trial design, predict the completion outcome and termination type (if applicable).